CAMBRIDGE, Mass., Oct 23, 2015 (BUSINESS WIRE) — InVivo Therapeutics Holdings Corp. (NVIV) today announced a 12-month post-implant update for the first study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold™ in patients with complete acute spinal cord injury. In